Last Price
1,075.00
Today's Change
-25.00 (2.27%)
Day's Change
972.01 - 1,160.00
Trading Volume
42,534
Profile
HEMO
Exchange: London Stock Exchange London Stock Exchange
Currency: GBp GBp
Sector: Healthcare - Healthcare Healthcare - Healthcare
CEO: Vladislav Sandler Vladislav Sandler
Full Time Employees: 16 16
IPO Date: 2015-11-09 2015-11-09
Description
Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML), subset of acute lymphoblastic leukaemia, and myelodysplastic syndrome conditioning bone marrow transplants to substitute traditional chemotherapy and/or radiation; HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants. The company was founded in 2012 and is headquartered in London, the United Kingdom.
Address
Discussions
Be the first to like this.
Showing 0 of 0 comments
Post a Comment
Latest Videos
![[New IPO] Hock Soon Capital Berhad, a leading Malaysian egg producer, expands to meet growing local and regional demand, plans to list on the Main Market!](https://mqac.i3investor.com/img/video_thumbnail/1419/Thumbnail__(25).png)
Apps
Top Articles
1
Stumbling and Mumbling
Daily Stocks
Stock
Last
Change
Volume
Stock
Last
Change
Volume
Stock
Last
Change
Volume
Ride The Bull Short The Bear
CS Tan
4.9 / 5.0
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
{uid}
{comment}
Just now